JP2024544520A5 - - Google Patents

Info

Publication number
JP2024544520A5
JP2024544520A5 JP2024527384A JP2024527384A JP2024544520A5 JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5 JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024527384 A JP2024527384 A JP 2024527384A JP 2024544520 A5 JP2024544520 A5 JP 2024544520A5
Authority
JP
Japan
Prior art keywords
amino acid
region
seq
acid sequence
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544520A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/081225 external-priority patent/WO2023083846A1/en
Publication of JP2024544520A publication Critical patent/JP2024544520A/ja
Publication of JP2024544520A5 publication Critical patent/JP2024544520A5/ja
Pending legal-status Critical Current

Links

JP2024527384A 2021-11-10 2022-11-09 抗体分子及び複合体 Pending JP2024544520A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163263835P 2021-11-10 2021-11-10
US63/263,835 2021-11-10
PCT/EP2022/081225 WO2023083846A1 (en) 2021-11-10 2022-11-09 Antibody molecules and conjugates

Publications (2)

Publication Number Publication Date
JP2024544520A JP2024544520A (ja) 2024-12-03
JP2024544520A5 true JP2024544520A5 (https=) 2025-10-20

Family

ID=84387847

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527384A Pending JP2024544520A (ja) 2021-11-10 2022-11-09 抗体分子及び複合体

Country Status (14)

Country Link
US (2) US12065496B2 (https=)
EP (1) EP4429765A1 (https=)
JP (1) JP2024544520A (https=)
KR (1) KR20240099430A (https=)
CN (1) CN118556084A (https=)
AR (1) AR127629A1 (https=)
CA (1) CA3237211A1 (https=)
CL (1) CL2024001384A1 (https=)
CO (1) CO2024007192A2 (https=)
EC (1) ECSP24044371A (https=)
IL (1) IL312566A (https=)
MX (1) MX2024005712A (https=)
TW (1) TW202336037A (https=)
WO (1) WO2023083846A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3259492A1 (en) * 2022-06-27 2024-01-04 Astrazeneca Ab COMBINATIONS INVOLVING EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
TW202527997A (zh) * 2023-11-15 2025-07-16 大陸商四川科倫博泰生物醫藥股份有限公司 靶向ｅｇｆｒ／ｃ—ｍｅｔ之抗體—藥物結合物以及其製備方法及用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates
WO2025108427A1 (zh) * 2023-11-23 2025-05-30 橙帆生物医药公司 结合分子及抗体药物偶联物和用途
CN117659203B (zh) * 2023-12-06 2024-08-13 科弈(浙江)药业科技有限公司 一种抗met/egfr双特异性抗体及其药物偶联物
WO2025230409A1 (en) * 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230410A1 (en) * 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2026021476A1 (en) 2024-07-24 2026-01-29 Beone Guangzhou Biologics Manufacturing Co., Ltd. Anti-cmet and anti-egfr multispecific antibody drug conjugates

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US7776814B2 (en) 2002-07-09 2010-08-17 R&D-Biopharmaceuticals Gmbh Tubulysin conjugates
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
CL2008001334A1 (es) 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
NZ584514A (en) 2007-10-19 2012-07-27 Genentech Inc Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
JP2013535220A (ja) 2010-08-06 2013-09-12 エンドサイト，インコーポレイテッド ツブリシンを調製するためのプロセス
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
KR102089591B1 (ko) * 2013-07-29 2020-03-18 삼성전자주식회사 항 EGFR scFv 단편 및 이를 포함하는 항 c-Met/항 EGFR 이중 특이 항체
EA032203B1 (ru) 2014-04-11 2019-04-30 МЕДИММЬЮН ЭлЭлСи Производные тубулизина
CN108350078A (zh) * 2015-11-03 2018-07-31 默克专利股份公司 用于提高肿瘤选择性和抑制的双特异性抗体及其用途
JP7325339B2 (ja) * 2017-05-30 2023-08-14 チョン クン ダン ファーマシューティカル コーポレーション 新規な抗ｃ－Ｍｅｔ抗体およびその用途

Similar Documents

Publication Publication Date Title
JP2024544520A5 (https=)
JP7118117B2 (ja) 抗体－薬物コンジュゲートの選択的製造方法
CN117946274B (zh) 抗cd73抗体及其应用
TWI564306B (zh) 雙特異性抗體
CN114106190B (zh) 一种抗vegf/pd-l1双特异性抗体及其用途
ES2773504T3 (es) Nuevo polipéptido que tiene afinidad por PD-L1
WO2019173832A2 (en) Novel cytokine prodrugs
ES3035714T3 (en) Edb targeting il-12 compositions
JP2020537520A5 (https=)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
CN105209493A (zh) 用于诊断和治疗用途的her3特异性单克隆抗体
CN114981301B (zh) Pd1和vegfr2双结合剂
CN115335400A (zh) 结合整合素avb8的抗体及其用途
JP2014515600A5 (https=)
JP2020532523A (ja) 抗ｅｇｆｒ抗体薬物コンジュゲート（ａｄｃ）及びその使用
KR20230171465A (ko) 항cldn4-항cd137 이중특이성 항체
CN119343378A (zh) 靶向itga2的抗体和包含此抗体的抗体药物缀合物
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
CN117659194B (zh) 靶向egfr的纳米抗体、药物偶联物及其用途
CN115558029A (zh) 靶向pd-1的双特异性抗体、及其制备和应用
CN114773485B (zh) 抗人PD-L1抗体和TGFβRII的双功能融合蛋白分子
CN121311503A (zh) 靶向itga2的抗体、其抗体药物缀合物以及用途
WO2025157266A1 (zh) 一种Nectin-4抗体及其应用
CN119744272A (zh) 一种抗ror1蛋白的抗体及其缀合物
CN118994393A (zh) 一种抗fgfr2抗体及其应用